

Time (CET) (column to be)	Time (CET)	Talk title*	Speaker	Time (CET)	Talk title*	Speaker(s)
		Monday 27 November 2023			Tuesday 28 November 2023	
09:00				09:00 - 9:40	<i>Patient-derived organoids (PDOs) for large-scale functional screen of dual-targeting bispecific antibodies [TBC]</i>	Ludovic Bourre Crown Bioscience
09:15				9:40 - 10:20	<i>A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity [TBC]</i>	Kathryn Simpson CRUK Manchester Institute, UK
09:30				10:20 - 11:00	Coffee break	
09:45				11:00 - 12:00	Round table : Preclinical patient-derived models: current status and future perspectives	Participants: All invited speakers Moderated by Jos Jonkers , Netherlands Cancer Institute (NKI)
10:00	10:00 - 11:30	(Venue opening)		12:00 - 12:40	<i>PDOs and PDX models in rare cancers. [TBC]</i>	Jordi Martinez Vall d'Hebron Institute of Oncology (VHIO), Spain
10:15				12:40 - 13:40	Lunch break	
10:30				13:40 - 14:20	<i>CancerModels.Org: an open global research platform for patient-derived cancer models. [TBC]</i>	Zinaida Perova EMBL-EBI, UK
10:45				14:20 - 15:20	<i>PDXNet, PDX-omics and pharmacogenomics [TBC]</i>	Keynote speaker: Jeffrey Chuang Jackson Laboratory, USA
11:00	11:30 - 12:00	<i>Welcome and opening remarks: EurOPDX: past, present and future.</i>	Sergio Roman-Roman Institut Curie, France	15:20 - 15:30	<i>Closing remarks and farewell</i>	Sergio Roman-Roman Institut Curie, France
11:15				15:30	End of the meeting	
11:30	12:00 - 12:40	<i>Precision oncology using PDX models of metastatic colorectal cancer [TBC]</i>	Livio Trusolino University of Torino, Italy			
11:45						
12:00	12:40 - 14:00	Lunch break				
12:15						
12:30						
12:45						
13:00						
13:15						
13:30						
13:45						
14:00	14:00 - 15:00	<i>A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology [TBC]</i>	Keynote speaker: Alana Welm Huntsman Cancer Institute, USA			
14:15						
14:30						
14:45						
15:00	15:00 - 15:40	<i>A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression [TBC]</i>	Stefan J. Hutten Netherlands Cancer Institute (NKI), NL			
15:15						
15:30						
15:45	15:40 - 16:10	Coffee break				
16:00						
16:15	16:10 - 16:50	<i>Biomarker discovery and validation in breast cancer PDX models [TBC]</i>	Violeta Serra Vall d'Hebron Institute of Oncology (VHIO), Spain			
16:30						
16:45						
17:00	16:50 - 17:30	<i>Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers [TBC]</i>	Elisabetta Marangoni Institut Curie, France			
17:15						
17:30						
17:45	17:30 - 17:45	<i>Sponsor's talk: Champions Oncology, France</i>	Stefano Cairo			
18:00	17:45 - 18:00	<i>[Sponsor's name, Country]</i>	<i>[Name Surname]</i>			
18:15						
18:30	18:00 - 19:30	(free time)				
18:45						
19:00						
19:15						
19:30						
19:45						
20:00	Starting at 19:30	Social dinner				
20:15						
20:30						
20:45						
21:00						
21:15						
21:30						

Legend
Invited guest speaker
Invited EurOPDX speaker
Invited industry speaker
Sponsor's talk
Round table
Coffee break or lunch
Social dinner
TBC: To Be Consolidated
*: speakers and topics are consolidated while final titles are still under discussion.

Program version: 05 (all speakers confirmed + sponsors' talks + JM); last update: 10 July 2023